Sandra and Edward Meyer Cancer Center

The aging liver undergoes dramatic changes in its functional organization and other key attributes, which may underpin its increasing susceptibility to disease, according to a study led by investigators at Weill Cornell Medicine.

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to a preclinical study led by Weill Cornell Medicine investigators. 

Dr. Nancy Du highlights the goals of a recently paused Department of Defense grant—and the consequences of further inaction.

The award recognizes exceptional junior investigators for their notable research achievements, impactful findings and high potential for success as independent investigators.

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.

Dr. Juan R. Cubillos-Ruiz and Dr. David Lyden have been named inaugural recipients of the Pershing Square Foundation’s 2025 Ovarian Cancer Challenge Grant.

Four Weill Cornell Medicine investigators received the Ritu Banga Healthcare Disparities Research Awards, recognizing innovative research that will help close care gaps in clinical settings.

Weill Cornell Medicine has received a projected $4 million grant from the National Cancer Institute, part of the National Institutes of Health, to conduct a clinical trial testing whether a new imaging approach could reduce the need for biopsies to monitor prostate cancer.

A tiny chemical modification commonly found on messenger RNAs plays a surprisingly large role in how cells respond to stress, according to a study led by Weill Cornell Medicine investigators.

A new study from Weill Cornell Medicine provides insights into how cells maintain the tiny end caps of chromosomes as they divide, a key process in keeping cells healthy. Using yeast, the researchers reveal protein interactions that could explain how the enzyme telomerase is tightly regulated to prevent cells from dividing uncontrollably or aging prematurely.

The way DNA folds inside the nucleus of brain cells may hold the key to understanding a devastating form of brain cancer called glioblastoma, suggests a new preclinical study from Weill Cornell Medicine researchers.

Bacteria naturally present in the human intestine, known as the gut microbiota, can transform cholesterol-derived bile acids into powerful metabolites that strengthen anti-cancer immunity by blocking androgen signaling, according to a preclinical study led by Weill Cornell Medicine investigators.

A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods and may be useful for monitoring disease status in patients following treatment, according to a study by Weill Cornell Medicine and New York Genome Center investigators.

Linoleic acid, an omega-6 fatty acid found in seed oils such as soybean and safflower oil, and animal products including pork and eggs, specifically enhances the growth of the hard-to-treat “triple negative” breast cancer subtype, according to a preclinical study led by Weill Cornell Medicine investigators. 

Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more effective model for predicting how patients with muscle-invasive bladder cancer will respond to chemotherapy.

With a mission to understand how nutrition and metabolism impact the body’s ability to control cancer, four leading research institutions have united under the Weill Cancer Hub East, an innovative, collaborative partnership that aims to transform cancer treatment.

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study led by Weill Cornell Medicine investigators.

Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study led by Weill Cornell Medicine investigators. 

Two Weill Cornell Medicine physician-scientists, Dr. Niroshana Anandasabapathy and Dr. Rohit Chandwani, have been elected members of the American Society for Clinical Investigation (ASCI) for 2025.

Blood clots form in response to signals from the lungs of cancer patients—not from other organ sites, as previously thought—according to a preclinical study by Weill Cornell Medicine.